{"disease":{"id":"gastro-esophageal-junction-cancer","name":"gastro esophageal junction cancer"},"drugs":{"marketed":[{"drug_id":"capecitabine","indication_name":"Treatment of unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07260734","title":"AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT07431281","title":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2130,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02872116","title":"Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2031,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT02538562","title":"Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":1695,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04152499","title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT03221426","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1007,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT04895709","title":"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":949,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03170960","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":914,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT07392892","title":"A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":840,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06093425","title":"Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":820,"lead_sponsor_name":"Suzhou Transcenta Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT06585501","title":"A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China","phase":"","overall_status":"COMPLETED","enrollment_count":805,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT06324357","title":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":768,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT06791538","title":"Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"Southwest Hospital, China","has_results":false},{"nct_id":"NCT04950322","title":"A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":737,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT06731478","title":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":726,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT06786169","title":"The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06346392","title":"AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":572,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03504397","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06532006","title":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":550,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT03653507","title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":507,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06901531","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT03175224","title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Apollomics Inc.","has_results":false},{"nct_id":"NCT01813253","title":"Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":400,"lead_sponsor_name":"Kuhnil Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05677490","title":"mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":382,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT06902545","title":"A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.","phase":"","overall_status":"RECRUITING","enrollment_count":377,"lead_sponsor_name":"Astellas Pharma Korea, Inc.","has_results":false},{"nct_id":"NCT02625623","title":"Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":371,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07408999","title":"Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":327,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT07090499","title":"A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06101277","title":"Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT01107639","title":"Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":297,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT06293898","title":"Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":280,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT06005493","title":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":280,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06452329","title":"A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05836584","title":"Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":240,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06219941","title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06203600","title":"Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06445972","title":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06662110","title":"IMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":206,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT04032704","title":"A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":205,"lead_sponsor_name":"Seagen Inc.","has_results":true},{"nct_id":"NCT01196390","title":"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":203,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06632262","title":"A Phase 2 Clinical Study of ABSK061 and ABSK043","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":202,"lead_sponsor_name":"Abbisko Therapeutics Co, Ltd","has_results":false},{"nct_id":"NCT06814548","title":"Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Yongxu Jia","has_results":false},{"nct_id":"NCT04805307","title":"Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"Keymed Biosciences Co.Ltd","has_results":false},{"nct_id":"NCT02443324","title":"A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT06157892","title":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}